We are live on ! Find out more
VINC

Vincerx Pharma, Inc. Common Stock
VINC

Delisted

VINC was delisted on the 22nd of April, 2025.

Back to rankings

42 hedge funds and large institutions have $18.6M invested in Vincerx Pharma, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

1% more capital invested

Capital invested by funds: $18.4M → $18.6M (+$166K)

18% less funds holding

Funds holding: 51 → 42 (-9)

38% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 13

64% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 14

Holders
42
Holders Change
-9
Holders Change %
-17.65%
% of All Funds
0.72%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
8
Reduced
13
Closed
14
Calls
$1.47M
Puts
–
Net Calls
+$1.47M
Net Calls Change
+$1.47M

Top Buyers

Rank Fund Capital Flow
1
RSCM
Rock Springs Capital Management
Maryland
+$423K
2
Russell Investments Group
Russell Investments Group
United Kingdom
+$297K
3
SSA
Schonfeld Strategic Advisors
New York
+$269K
4
AAA
Affinity Asset Advisors
New York
+$171K
5
ECM
ExodusPoint Capital Management
New York
+$104K

Top Sellers

Rank Fund Capital Flow
1
LFCM
Long Focus Capital Management
Puerto Rico
-$1.41M
2
PVI
Pura Vida Investments
New York
-$143K
3
Millennium Management
Millennium Management
New York
-$142K
4
SFM
Sphera Funds Management
Israel
-$93K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$82.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCMNY
1
Rubric Capital Management (New York)
New York
$2.91M – – –
SRC
2
Sage Rhino Capital
California
$2.29M – – –
AAA
3
Affinity Asset Advisors
New York
$2.06M +$171K +5,934 +9%
RSCM
4
Rock Springs Capital Management
Maryland
$1.53M +$423K +14,719 +36%
TCM
5
Tang Capital Management
California
$1.42M – – –
Holocene Advisors
6
Holocene Advisors
New York
$1.05M – – –
Citadel Advisors
7
Citadel Advisors
Florida
$863K +$2.36K +82 +0.3%
Vanguard Group
8
Vanguard Group
Pennsylvania
$720K -$82.4K -2,863 -10%
SM
9
Sabby Management
Florida
$698K +$7.19K +250 +1%
SSA
10
Schonfeld Strategic Advisors
New York
$663K +$269K +9,362 +64%
CC
11
Clearline Capital
New York
$624K – – –
KCM
12
Kingdon Capital Management
New York
$531K – – –
Point72 Asset Management
13
Point72 Asset Management
Connecticut
$476K – – –
Renaissance Technologies
14
Renaissance Technologies
New York
$426K -$5.5K -191 -1%
BBA
15
Baker Bros. Advisors
New York
$333K – – –
Millennium Management
16
Millennium Management
New York
$287K -$142K -4,949 -32%
Russell Investments Group
17
Russell Investments Group
United Kingdom
$284K +$297K +10,311 New
ECM
18
ExodusPoint Capital Management
New York
$238K +$104K +3,610 +72%
BlackRock
19
BlackRock
New York
$191K -$5.18K -180 -3%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$189K – – –
SCM
21
Sio Capital Management
New York
$141K – – –
E
22
Ergoteles
New York
$98K -$13.9K -484 -12%
LP
23
LMR Partners
United Kingdom
$87K – – –
Two Sigma Investments
24
Two Sigma Investments
New York
$75K -$7.77K -270 -9%
State Street
25
State Street
Massachusetts
$60K – – –
1
2 3

VINC Hedge Fund Activity: Q3 2022 in Review

42 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q3 2022, worth a combined $18.6M — up 0.9% from $18.4M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of VINC and 5 opened new positions — a net loss of 9 holders — while 13 trimmed existing stakes and 8 added.

The largest buyer was Rock Springs Capital Management, adding an estimated $423K. The largest seller was Long Focus Capital Management, exiting entirely with an estimated $1.41M sold.

  • 42 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q3 2022, down from 51 in Q2 2022.
  • Funds reported $18.6M of Vincerx Pharma, Inc. Common Stock stock for Q3 2022, up 0.9% quarter-over-quarter.
  • 5 funds opened new Vincerx Pharma, Inc. Common Stock positions in Q3 2022 and 14 closed out, a net change of -9 holders.
  • The largest Vincerx Pharma, Inc. Common Stock buyer in Q3 2022 was Rock Springs Capital Management, an estimated $423K added.
  • The largest Vincerx Pharma, Inc. Common Stock seller in Q3 2022 was Long Focus Capital Management, an estimated $1.41M sold.

Based on aggregated 13F filings for Q3 2022.